Want to see PPBT full AI Analyst Report?
PPBT Stock Chart & Stats
$4.87
-$0.22(-5.25%)
At close: 4:00 PM EST
$4.87
-$0.22(-5.25%)
Day’s Range― - ―
52-Week Range$1.35 - $29.00
Previous CloseN/A
Volume16.93K
Average Volume (3M)415.61K
Market Cap
$10.66M
Enterprise Value-$3.60M
Total Cash (Recent Filing)$6.43M
Total Debt (Recent Filing)$184.00K
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Jul 30, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9933.94
Shares Outstanding1,618,259
10 Day Avg. Volume296,099
30 Day Avg. Volume415,608
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit67.58
Enterprise Value/Ebitda0.69
Forecast
1Y Price Target
$30.00Price Target Upside516.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated CAPTN-3 Tri‑specific PlatformPurple Biotech's CAPTN-3 is a masked tri‑specific T‑cell engager that confines activation to the tumor microenvironment while engaging CD3 and NKG2A. That architecture addresses core safety limits of current TCEs, potentially expanding the therapeutic window and creating a durable competitive advantage and partner interest if clinical proof‑of‑concept is achieved.
Strong Preclinical PK/safety For IM1240Non‑human primate data showing substantially improved half‑life, exposure and low cytokine release materially lowers the clinical risk profile for IM1240. Durable improvements in PK and safety reduce attrition risk, support broader dosing strategies, and enhance the program's attractiveness to partners and acquirers over multiple development stages.
Experienced Scientific Advisory Board & Focused R&DAssembling a SAB of clinicians and translational experts and redirecting resources to CAPTN‑3 strengthens development strategy, trial design and go‑to‑market planning. This governance upgrade improves execution odds for early‑phase trials and increases the probability of efficient regulatory paths and strategic partnerships over the medium term.
Bears Say
No Meaningful Revenue; Persistent Net LossesThe company has effectively zero recent revenue while reporting large, persistent net losses. This structural absence of commercial income makes Purple Biotech reliant on external funding or partnerships to sustain operations and increases the risk that future financing or deal terms will be dilutive or contingent on achieving difficult clinical milestones.
Material Negative Cash GenerationSustained negative operating and free cash flow indicates recurrent funding needs through development. Over the 2–6 month horizon and beyond, negative cash generation elevates the probability of near‑term financings, which can dilute existing shareholders and constrain resource allocation until clinical or partner milestones restore self‑funding capacity.
Tight Cash Runway And Significant Equity ErosionWith only $6.4M and a runway into H1 2027, the company faces near‑term liquidity pressure. The balance sheet has also seen equity fall sharply (from ~$64.8M in 2021 to ~$9.7M in 2025/TTM), indicating capital erosion that raises fundraising frequency and dilution risk, threatening operational continuity absent partnerships or financing.
Purple Biotech News
PPBT FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $1.35 and its highest was $29.00 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is $10.66M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Jul 30, 2026 which is in 11 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on May 15, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.29.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -0.98.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,618,259 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went up 6.775%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
PPBT Stock 12 Month Forecast
Average Price Target
$30.00
▲(516.02% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.12% Other Institutional Investors
98.88% Public Companies and
Individual Investors